Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GBR1302 |
Synonyms | |
Therapy Description |
GBR1302 is a bispecific antibody that targets both ERBB2 (HER2) and CD3, which may have anti-tumor activity against ERBB2 (HER2)-positive tumors (European Journal of Cancer, Vol. 50, 48 (abst nr. 139), PMID: 32054397). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GBR1302 | GBR 1302|GBR-1302 | CD3 Antibody 99 HER2 (ERBB2) Antibody 76 | GBR1302 is a bispecific antibody that targets both ERBB2 (HER2) and CD3, which may have anti-tumor activity against ERBB2 (HER2)-positive tumors (European Journal of Cancer, Vol. 50, 48 (abst nr. 139), PMID: 32054397). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02829372 | Phase I | GBR1302 | Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101) | Terminated | USA | DEU | 0 |
NCT03983395 | Phase Ib/II | GBR1302 | Study of GBR 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer | Terminated | USA | 0 |